Profiling antimicrobial peptides from the medical maggot Lucilia sericata as potential antibiotics for MDR Gram-negative bacteria
dc.contributor.author | Hirsch, Rolf | |
dc.contributor.author | Wiesner, Jochen | |
dc.contributor.author | Marker, Alexander | |
dc.contributor.author | Pfeifer, Yvonne | |
dc.contributor.author | Bauer, Armin | |
dc.contributor.author | Hammann, Peter E. | |
dc.contributor.author | Vilcinskas, Andreas | |
dc.date.accessioned | 2019-03-22T09:00:21Z | |
dc.date.available | 2019-03-22T09:00:21Z | |
dc.date.issued | 2018-10-01 | none |
dc.identifier.other | 10.1093/jac/dky386 | |
dc.identifier.uri | http://edoc.rki.de/176904/6026 | |
dc.description.abstract | Background The ability of MDR Gram-negative bacteria to evade even antibiotics of last resort is a severe global challenge. The development pipeline for conventional antibiotics cannot address this issue, but antimicrobial peptides (AMPs) offer an alternative solution. Objectives Two insect-derived AMPs (LS-sarcotoxin and LS-stomoxyn) were profiled to assess their suitability for systemic application in humans. Methods The peptides were tested against an extended panel of 114 clinical MDR Gram-negative bacterial isolates followed by time–kill analysis, interaction studies and assays to determine the likelihood of emerging resistance. In further in vitro studies we addressed cytotoxicity, cardiotoxicity and off-target interactions. In addition, an in vivo tolerability and pharmacokinetic study in mice was performed. Results LS-sarcotoxin and LS-stomoxyn showed potent and selective activity against Gram-negative bacteria and no cross-resistance with carbapenems, fluoroquinolones or aminoglycosides. Peptide concentrations of 4 or 8 mg/L inhibited 90% of the clinical MDR isolates of Escherichia coli, Enterobacter cloacae, Acinetobacter baumannii and Salmonella enterica isolates tested. The ‘all-d’ homologues of the peptides displayed markedly reduced activity, indicating a chiral target. Pharmacological profiling revealed a good in vitro therapeutic index, no cytotoxicity or cardiotoxicity, an inconspicuous broad-panel off-target profile, and no acute toxicity in mice at 10 mg/kg. In mouse pharmacokinetic experiments LS-sarcotoxin and LS-stomoxyn plasma levels above the lower limit of quantification (1 and 0.25 mg/mL, respectively) were detected after 5 and 15 min, respectively. Conclusions LS-sarcotoxin and LS-stomoxyn are suitable as lead candidates for the development of novel antibiotics; however, their pharmacokinetic properties need to be improved for systemic administration. | eng |
dc.language.iso | eng | none |
dc.publisher | Robert Koch-Institut | |
dc.rights | (CC BY 3.0 DE) Namensnennung 3.0 Deutschland | ger |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/de/ | |
dc.subject | antibiotics | eng |
dc.subject | Gram-negative bacteria | eng |
dc.subject | insecta | eng |
dc.subject | peptides | eng |
dc.subject | plasma | eng |
dc.subject | mice | eng |
dc.subject | pharmacokinetics | eng |
dc.subject | pharmacology | eng |
dc.subject | antimicrobials | eng |
dc.subject | cytotoxicity | eng |
dc.subject | toxic effect | eng |
dc.subject.ddc | 610 Medizin und Gesundheit | none |
dc.title | Profiling antimicrobial peptides from the medical maggot Lucilia sericata as potential antibiotics for MDR Gram-negative bacteria | none |
dc.type | article | |
dc.identifier.urn | urn:nbn:de:kobv:0257-176904/6026-6 | |
dc.identifier.doi | http://dx.doi.org/10.25646/5991 | |
dc.type.version | publishedVersion | none |
local.edoc.container-title | Journal of Antimicrobial Chemotherapy | none |
local.edoc.type-name | Zeitschriftenartikel | |
local.edoc.container-type | periodical | |
local.edoc.container-type-name | Zeitschrift | |
local.edoc.container-url | https://academic.oup.com/jac/article/74/1/96/5113243 | none |
local.edoc.container-publisher-name | Oxford University Press | none |
local.edoc.container-volume | 74 | none |
local.edoc.container-issue | 1 | none |
local.edoc.container-reportyear | 2018 | none |
local.edoc.container-year | 2018 | none |
local.edoc.container-firstpage | 96 | none |
local.edoc.container-lastpage | 107 | none |
local.edoc.rki-department | Infektionskrankheiten | none |
dc.description.version | Peer Reviewed | none |